Document:

Document

Exhibit 10.3

EXECUTION VERSION
Yale Confidential

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is the type that the registrant customarily and actually treats as private and confidential.

TABLE OF CONTENTS
									
	1.	BACKGROUND	2
	2.	DEFINITIONS	2
	3.	LICENSE GRANT AND TERM	7
	4.	DUE DILIGENCE	8
	5.	LICENSE ISSUE ROYALTY; LICENSE MAINTENANCE ROYALTY; MILESTONE ROYALTIES	 
	6.	EARNED ROYALTIES	12
	7.	SUBLICENSES	14
	8.	CONFIDENTIALITY AND PUBLICITY	14
	9.	REPORTS, RECORDS AND INSPECTIONS	15
	10.	PATENT PROTECTION	16
	11.	INFRINGEMENT AND LITIGATION	17
	12.	USE OF YALE’S NAME	19
	13.	TERMINATION	19
	14.	INDEMNIFICATION; INSURANCE; NO WARRANTIES	21
	15.	NOTICES	23
	16.	INVENTOR AGREEMENTS	23
	17.	LAWS, FORUM AND REGULATIONS	23
	18.	MISCELLANEOUS	24

									
	[***]
	 -1- 
	

Yale Confidential

AMENDED AND RESTATED LICENSE AGREEMENT
THIS AMENDED AND RESTATED LICENSE AGREEMENT (the “Agreement”) by and between YALE UNIVERSITY, a corporation organized and existing under and by virtue of a charter granted by the general assembly of the Colony and State of Connecticut and located in New Haven, Connecticut (“YALE”), and IsoPlexis Corporation a company organized and existing under the laws of the State of Delaware, and with principal offices located in 51 Cottage St Unit 3, New Haven, Connecticut (“LICENSEE”) is entered into as of the date of final signature below (the “RESTATEMENT DATE”).

1.    BACKGROUND
1.1.    In the course of research conducted under YALE auspices, Dr. Rong Fan, in the Department of BioMedical Engineering at YALE (the “INVENTOR”), has produced an invention entitled [***] (the “INVENTION”).
1.2.    INVENTOR has assigned to YALE all of INVENTOR’s right, title and interest in and to the INVENTION and any resulting patents. 
1.3.    YALE wishes to have the INVENTION and any resulting patents commercialized to benefit the public good.  
1.4.    LICENSEE has represented to YALE to induce YALE to enter into this Agreement that it shall act diligently to develop and commercialize the LICENSED PRODUCTS for public use throughout the LICENSED TERRITORY (as defined below).
1.5.    YALE and LICENSEE entered into a License Agreement (the “ORIGINAL AGREEMENT”) effective as of April 25, 2014 pursuant to which YALE granted a license to LICENSEE, subject to the terms and conditions of the Original Agreement, as amended and restated on July 15, 2014.
1.6.    YALE and LICENSEE now desire to amend, restate and supersede the Original Agreement, as amended and restated on July 15, 2014, in its entirety.
1.7.    In consideration of these statements and mutual promises, YALE and LICENSEE agree to the terms of this Agreement.

2.    DEFINITIONS
The following terms used in this Agreement shall be defined as set forth below:
2.1.    “AFFILIATE” shall mean any entity or person that directly or indirectly controls, is controlled by or is under common control with LICENSEE.  For purposes of this definition, “control” means possession of the power to direct the management of such entity or person, whether through ownership of more than fifty percent (50%) of voting securities, by contract or otherwise.
									
	[***]
	 -2- 
	

Yale Confidential

2.2.    “AGGREGATE NET PROCEEDS” shall mean the amount distributed or available for distribution to the LICENSEE’s members or stockholders, as and when such amounts are paid to the LICENSEE or its stockholders, after the payment of all liabilities and expenses of the transaction; without limiting the foregoing, any amounts associated with earn outs, escrows and the like will be included in AGGREGATE NET PROCEEDS as and when such amounts are paid to the LICENSEE or its stockholders.  
2.3    ”CHANGE OF CONTROL” shall mean:
(a)    any consolidation, merger, combination, reorganization, or other transaction in which LICENSEE is not the surviving entity and in which the holders of the voting securities of LICENSEE do not, after giving effect to such consolidation, merger, combination, reorganization, or other transaction, continue to hold more than fifty percent (50%) of the voting securities of the surviving entity; provided that (i) the conversion of LICENSEE from a limited liability company to a corporation (a “CONVERSION”) and (ii) a CONVERSION together with the sale of equity securities for financing purposes (even if more than fifty percent (50%) of the voting securities of LICENSEE are sold in such a transaction), shall not be deemed CHANGES OF CONTROL hereunder; or 
(b)     the membership interests or other equity securities of LICENSEE constituting in excess of fifty percent (50%) of the voting power of LICENSEE are exchanged for or changed into stock or other securities of another person, cash, or any other property of another person such that the holders of the voting securities of LICENSEE do not, after giving effect to such transaction, continue to hold more than fifty percent (50%) of the voting securities of LICENSEE or 
(c)    a sale or other disposition of all or substantially all of the assets of LICENSEE.
2.4.    “CONFIDENTIAL INFORMATION” shall mean all information disclosed by one party to the other during the negotiation of or under this Agreement in any manner, whether orally, visually or in tangible form, that relates to LICENSED PATENTS or the Agreement itself, unless such information is subject to an exception described in Article 8.2; provided, however, that CONFIDENTIAL INFORMATION that is disclosed in tangible form shall be marked “Confidential” at the time of disclosure and CONFIDENTIAL INFORMATION that is disclosed orally or visually shall be identified as confidential at the time of disclosure and subsequently reduced to writing, marked confidential and delivered to the other party within [***] days of such disclosure.  CONFIDENTIAL INFORMATION shall include, without limitation, materials, know-how and data, technical or non-technical, trade secrets, inventions, methods and processes, whether or not patentable.  Notwithstanding any other provisions of this Article 2.2, CONFIDENTIAL INFORMATION of LICENSEE that is subject to Article 8 of this Agreement is limited to information that LICENSEE supplies pursuant to LICENSEE’s obligations under Articles 7 and 9 of this Agreement, unless otherwise mutually agreed to in writing by the parties.
2.5.    “EARNED ROYALTY” is defined in Article 6.1.
									
	[***]
	 -3- 
	

Yale Confidential

2.6.    “EFFECTIVE DATE” is April 25, 2014, which is the effective date of the Original Agreement.
2.7.    “EXCHANGEABLE PROMISSORY NOTE” shall mean an instrument in substantially the form of Exhibit A that contains an express and absolute promise of LICENSEE to pay to YALE a defined sum of money, plus specified interest, at a specified time and that is exchangeable at the option of YALE into a security in the form of a convertible note or other convertible debt or any class of equity shares available at the time of conversion.  
2.8.    “FIELD” shall mean all fields of use.
2.9.    “FIRST SALE” shall mean the first sale, lease or other transfer, practice or disposition to a third party of any LICENSED PRODUCT in any country.
2.10.    “INVENTION” and “INVENTOR” are defined in Article 1.1.
2.11.    “INVENTOR AGREEMENT” shall mean a consulting or other agreement directly between LICENSEE and an INVENTOR.
2.12.    “INSOLVENT” shall mean that (i) an involuntary proceeding shall have been commenced or an involuntary petition shall have been filed seeking (a) liquidation, reorganization or other relief in respect of LICENSEE or its debts, or of a substantial part of its assets, under any Federal, state or foreign bankruptcy law or (b) the appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for LICENSEE or for a substantial part of its assets, and, in any such case, such proceeding or petition shall continue undismissed for a period of [***] days or (ii) LICENSEE shall have voluntarily (a) commenced any proceeding or filed any petition seeking liquidation, reorganization or other relief under any Federal, state or foreign bankruptcy law or (b) applied for or consented to the appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for LICENSEE or for a substantial part of its assets.
2.13.    “LICENSE” refers to the license granted under Article 3.1.
2.14.    “LICENSED INFORMATION” shall mean all inventions, biological materials and reagents, devices, patent applications, concepts, processes, information, data, know-how and the like including software, listed in Appendix B, that are owned or co-owned by YALE as of the EFFECTIVE DATE, discovered in or on behalf of the laboratory of the INVENTOR (including, without limitation, by outsourced third parties and consultants), and necessary or useful for the discovery, development, manufacture, use or sale of LICENSED PRODUCTS, or for the practice of the LICENSED METHODS.
2.15.    “LICENSED METHOD” shall mean any method, procedure, service or process the practice of which, is claimed by a VALID CLAIM of a LICENSED PATENT, or which uses a LICENSED PRODUCT of the type defined in subsection (a) of the definition of LICENSED PRODUCT, or which utilizes, in part or in whole, LICENSED INFORMATION for such method, procedure, process, or service.  
2.16.    “LICENSED PATENTS” shall mean the United States or foreign patent application(s) and patents(s) listed in Appendix A and owned by YALE during the term of this Agreement, together with any continuations, divisionals, and continuations-in-part, to the extent the claims of any such patent or patent
									
	[***]
	 -4- 
	

Yale Confidential

application are directed to subject matter specifically described in the patent applications listed on Appendix A; any reissues, re-examinations, or extensions thereof, or substitutes therefor; and the relevant international equivalents of any of the foregoing. Appendix A is incorporated into this Agreement.  
2.17.    “LICENSED PRODUCT” shall mean 
(a)    any product (including any apparatus or kit) or component part thereof, if the manufacture, use, sale, import, export or practice thereof is claimed by a VALID CLAIM of a LICENSED PATENT, or which utilizes, in part or in whole, LICENSED INFORMATION for its discovery, development, manufacture, use, or sale. 
(b)    any LICENSED METHOD.
2.18.    “LICENSED TERRITORY” shall mean worldwide.
2.19.    “NET SALES” shall mean:
(a)    gross invoice price from the sale, lease or other transfer, practice or disposition of the LICENSED PRODUCTS, or from services performed using or constituting LICENSED PRODUCTS   by LICENSEE, SUBLICENSEES or AFFILIATES to third parties, except as set forth in Article 2.19(b), less the following deductions, provided they actually pertain to the disposition of the LICENSED PRODUCTS and are separately invoiced:
(i)    all discounts, credits and allowances on account of returns;
(ii)    transportation and insurance; 
(iii)    duties, taxes and other governmental charges levied on the sale, transportation, delivery or practice of LICENSED PRODUCTS, but not including income taxes; and
(iv)    reimbursement of documented direct costs for performing services or LICENSED METHODS pursuant to a services agreement and prior to the [***] Anniversary of the RESTATEMENT DATE, which shall include reimbursement of out-of-pocket expenses and payments for full-time equivalent (“FTE”) efforts of personnel performing services or LICENSED METHODS.  Upon mutual written agreement of the parties, the deduction in this Section 2.19 (a) (iv) may be extended beyond the [***] Anniversary of the RESTATEMENT DATE, provided that neither party shall be obligated to agree to such extension.
Except as provided in Section 2.19(a)(iv) above, no deductions shall be made for any other costs or expenses, including but not limited to commissions to independents, agents or those on LICENSEE’s or an AFFILIATE’s payroll or for the cost of collection.
(b)    “NET SALES” shall not include the gross invoice price for LICENSED PRODUCTS sold to, or services performed using LICENSED PRODUCTS 
									
	[***]
	 -5- 
	

Yale Confidential

for, any AFFILIATE unless such AFFILIATE is an end-user of any LICENSED PRODUCT, in which case such consideration shall be included in NET SALES at the average selling price charged to a third party during the same quarter.
2.20.    “PATENT CHALLENGE” shall mean a challenge or opposition to the validity, patentability, enforceability and/or non-infringement of any of the LICENSED PATENTS or otherwise opposing any of the LICENSED PATENTS.
2.21.    “PREFERRED STOCK” means the Series A stock issued to investors in connection with a SUCCESSFUL FINANCING.
2.22.    "REASONABLE COMMERCIAL EFFORTS" shall mean documented efforts that are consistent with those utilized by companies of similar size and type that have successfully developed products and services similar to LICENSED PRODUCTS and LICENSED METHODS. In determining REASONABLE COMMERCIAL EFFORTS with respect to a particular LICENSED PRODUCT or LICENSED METHOD, LICENSEE may not reduce such efforts due to the competitive, regulatory or other impact of any other product or method that it owns, licenses or is developing or commercializing. 
2.23.    “SUBLICENSE INCOME” shall mean consideration in any form received by LICENSEE or an AFFILIATE in connection with a grant to any third party or parties of a sublicense, cross-license, option, or other right, license, privilege or immunity to make, have made, use, sell, have sold, distribute, practice, import or export LICENSED PRODUCTS, but excluding consideration included within EARNED ROYALTIES.  SUBLICENSE INCOME shall include without limitation any license signing fee, license maintenance fee, option fee or other payment pursuant to an option, unearned portion of any minimum royalty payment received by LICENSEE, distribution or joint marketing fee, and research and development funding in excess of LICENSEE’s cost of performing such research and development.  In the event a sublicense includes technology other than the LICENSED PATENTS, or in the event that the LICENSED PATENTS are sublicensed to a third party in a separate agreement from LICENSEE’s patents that are licensed to the same third party, the SUBLICENSE INCOME will be reduced by an amount proportional to the relative value of such other technology in accordance with an adjustment formula to be agreed to in writing by the parties. For the avoidance of doubt, any consideration received by LICENSEE or an AFFILIATE for LICENSED METHODS shall constitute NET SALES according to 2.19, but not SUBLICENSE INCOME.
2.24.    “SUBLICENSEE” shall mean any third party sublicensed by LICENSEE to make, have made, use, sell, have sold, import or export or practice any LICENSED PRODUCT. 
2.25.    “SUCCESSFUL FINANCING” shall mean a bona fide investment in LICENSEE from a single investor or group of investors of [***].
2.26.    “TERM” is defined in Article 3.4.
2.27.    “VALID CLAIM” shall mean a pending, issued or unexpired claim of a LICENSED PATENT so long as such claim shall not have been irrevocably abandoned or 
									
	[***]
	 -6- 
	

Yale Confidential

declared to be invalid in an unappealable decision of a court or other authority or competent jurisdiction through no fault or cause of LICENSEE
3.    LICENSE GRANT AND TERM
3.1.    Subject to all the terms and conditions of this Agreement, and upon payment to YALE of the consideration described in Article 5, or execution and delivery of an EXCHANGEABLE PROMISSORY NOTE, YALE hereby grants to LICENSEE an exclusive license, with the right to grant sublicenses subject to the terms in section 7, subject to the reservation of rights by YALE under Article 3.3, under the LICENSED PATENTS and LICENSED INFORMATION to make, have made, use, sell, have sold, import, export, or practice LICENSED PRODUCTS within the FIELD in the LICENSED TERRITORY (the "LICENSE").
3.2.    To the extent that any invention included within the LICENSED PATENTS has been funded in whole or in part by the United States government, the United States government retains certain rights in such invention as set forth in 35 U.S.C. §200-212 and all regulations promulgated thereunder, as amended, and any successor statutes and regulations (the “Federal Patent Policy”).  As a condition of the license granted hereby, LICENSEE acknowledges and shall comply with all aspects of the Federal Patent Policy applicable to the LICENSED PATENTS, including the obligation that LICENSED PRODUCTS used or sold in the United States be manufactured substantially in the United States.  Nothing contained in this Agreement obligates or shall obligate YALE to take any action that would conflict in any respect with its past, current or future obligations to the United States Government under the Federal Patent Policy with respect to the LICENSED PATENTS.
3.3.    The LICENSE is expressly made subject to YALE’s reservation of the right, on behalf of itself and all other non-profit academic and/or research institutions, to make, use and practice the LICENSED PATENTS and LICENSED PRODUCTS for research, clinical, teaching or other non-commercial purposes, and not for purposes of commercial development, use, manufacture or distribution, and subject to YALE’s reservation of the right on behalf of itself and other collaborating non-profit academic institutions to use and modify the software for research and educational purposes.
3.4.    Unless terminated earlier as provided in Article 13, the term of this Agreement (the "TERM") shall commence on the EFFECTIVE DATE and shall automatically expire on the later of: i) on a country-by-country basis, on the date on which the last of the claims of the patents described in the LICENSED PATENTS in such country expires, lapses or is declared to be invalid by a non-appealable decision of a court or other authority of competent jurisdiction through no fault or cause of LICENSEE; or ii) ten (10) years after the date of FIRST SALE in such country.  Upon expiration of the TERM (but not earlier termination as provided in Article 13) of this Agreement in each country, all rights and licenses granted by YALE to LICENSEE hereunder that were in effect immediately prior to the effective date of such expiration, including rights in the LICENSED INFORMATION, shall become non-exclusive, irrevocable, perpetual and fully-paid.
3.5.    Nothing in this Agreement shall be construed to grant by implication, estoppel or otherwise any licenses under patents of YALE other than the LICENSED PATENTS and LICENSED INFORMATION.   Except as expressly provided in this Agreement, under no circumstances will LICENSEE, as a result of this 
									
	[***]
	 -7- 
	

Yale Confidential

Agreement, obtain any interest in or any other right to any technology, know-how, patents, patent applications, materials or other intellectual or proprietary property of YALE.

4.    DUE DILIGENCE
4.1.    LICENSEE has designed a plan for developing and commercializing the LICENSED PATENTS that includes a description of research and development, testing, government approval, manufacturing, marketing and sale or lease of LICENSED PRODUCTS (“PLAN”).  A copy of the PLAN is attached to this agreement as Appendix C and incorporated herein by reference.
4.2.    LICENSEE shall use all REASONABLE COMMERCIAL EFFORTS, within [***] days after the EFFECTIVE DATE of this Agreement, to begin to implement the PLAN at its sole expense and thereafter to fully implement the PLAN and to diligently commercialize and develop markets for the LICENSED PRODUCTS.
4.3.    [***] after the EFFECTIVE DATE of this Agreement, and on or prior to [***] anniversary of the EFFECTIVE DATE, LICENSEE shall provide YALE with an updated and revised copy of the PLAN which shall indicate LICENSEE’s progress and problems to date in development and commercialization of LICENSED PRODUCTS and a forecast and schedule of major events required to market the LICENSED PRODUCTS.  Such updated PLAN shall clearly indicate which of LICENSEE’s products or services are LICENSED PRODUCTS, and which LICENSED PATENTS claim each such LICENSED PRODUCT. 
(a)    At least [***] days prior to assignment by LICENSEE pursuant to Article 18.6, the assignee shall provide YALE with an updated and revised copy of the PLAN. 
(b)    YALE shall review and by notice in writing to assignee may approve or disapprove of any updated and revised PLAN provided in accordance with Article 4.3 in its sole discretion, such approval not to be unreasonably withheld.
4.4.    LICENSEE shall immediately send YALE a notice of abandonment if at any time LICENSEE (a) abandons or suspends its research, development or marketing of the LICENSED PRODUCTS, or its intent to research, develop and market LICENSED PRODUCTS, or (b) fails to comply with its obligations under this Article for a period exceeding [***] days.
4.5.    LICENSEE shall not, independently or with or through a third party, engage directly or indirectly in the development, manufacture, marketing, sale or distribution of any product or method other than the LICENSED PRODUCTS that are competitive with the LICENSED PRODUCTS.
4.6.    LICENSEE agrees that YALE shall be entitled to terminate this Agreement pursuant to Article 13.1(b) upon the occurrence of any of the following:
(a)    LICENSEE shall fail to provide the written reports as provided in Article 4.3 within [***] business days after receipt of written notice from YALE of its failure to do so; or 
									
	[***]
	 -8- 
	

Yale Confidential

(b)    LICENSEE shall fail to receive written approval of the PLAN as defined in Article 4.1 or Article 4.2, or assignee of LICENSEE shall fail to receive written approval of the PLAN as provided in Article 4.3(a); or 
(c)    LICENSEE shall fail to implement the PLAN in accordance with this Article or otherwise fails to fulfill any of its obligations under this Article 4; or 
(d)    LICENSEE gives notice pursuant to Article 4.4 (which shall be deemed a material breach not capable of being cured); or
(e)    Upon the occurrence of any of the events set forth in Section 4.4 or 4.5; or
(f)    LICENSEE has failed to 
(i)    incur direct expenses for research and development (including clinical development), or marketing of LICENSED PRODUCTS according to the following schedule (“Committed Spend”):
[***]
(ii)    make a FIRST SALE of a LICENSED PRODUCT within [***] years of the EFFECTIVE DATE; or 
(iii)    receive financing, grant support, or other funds of [***]; or
(iv)    achieve a SUCCESSFUL FINANCING within [***] years of the EFFECTIVE DATE
In the event that LICENSEE spends less than the required amount in 4.6 (f) (i) in any given year, LICENSEE may make up for such shortfall over [***] period by spending the amount required in each of the following [***] years plus the amount of such shortfall.  Such carry-over of any shortfall of Committed Spend shall be permitted only once during the TERM of the LICENSE.
Notwithstanding the foregoing in this Article 4.5, if LICENSEE has not employed REASONABLE COMMERCIAL EFFORTS in developing and selling LICENSED PRODUCTS on a country-by-country basis within the TERRITORY for any reason, then YALE may, at its sole discretion, terminate this LICENSE pursuant to Article 13 herein on a country-by-country basis.
									
	[***]
	 -9- 
	

Yale Confidential

4.7.    It is the desire of both YALE and LICENSEE to make LICENSED PRODUCTS available in the developing world, and it is the parties’ common desire for the LICENSEE to develop LICENSED PRODUCTS that are clinically and economically suited for use in those areas. To that end, YALE and LICENSEE agree:
(a)    LICENSEE shall make the use of LICENSED PRODUCTS in low-income and lower-middle-income countries (as defined by the World Bank) a part of its Corporate Mission Statement.
(b)    LICENSEE agrees that, upon achieving $[***] in cumulative NET SALES (determined in accordance with US generally accepted accounting principles) of LICENSED PRODUCTS, LICENSEE will commit an amount equal to [***] of NET SALES, in the form of LICENSED PRODUCTS valued at the gross invoice price or the equivalent dollar amount in the form of training, grants and/or services to governments in low-income and lower-middle income countries, not-for-profit charitable organizations such as Doctors Without Borders, or other such organizations, for the purpose of preventing or treating disease in low income or lower middle income countries.

5.    LICENSE ISSUE ROYALTY; LICENSE MAINTENANCE ROYALTY; MILESTONE ROYALTIES 
5.1.    LICENSEE shall pay to YALE on the EFFECTIVE DATE a non-refundable license issue royalty of [***] payable in the form of an EXCHANGEABLE PROMISSORY NOTE issued to YALE, wherein YALE can elect, in its sole discretion, to convert the EXCHANGEABLE PROMISSORY NOTE into LICENSEE’S PREFERRED STOCK based on the PREFERRED STOCK’s sale value.  In the event YALE receives LICENSEE’S PREFERRED STOCK, YALE agrees to become a signatory to all financing documents on the same basis as the other PREFERRED STOCK holders.
5.2.    During the TERM of this Agreement, LICENSEE agrees to pay to YALE an annual license maintenance royalty (“LMR”) commencing on the second anniversary of the EFFECTIVE DATE and every anniversary thereafter according to the following schedule:
[***]

									
	[***]
	 -10- 
	

Yale Confidential

5.3.    The license issue royalty set forth in Article 5.1 shall not be credited against EARNED ROYALTIES payable under Article 6.1.  The LMR of Article 5.2 shall be creditable against EARNED ROYALTIES due in the same calendar year payable under Article 6.1.
5.4.    During the term of this Agreement, LICENSEE agrees to pay YALE the following milestones:
-    1st sublicense agreement with a SUBLICENSEE: [***].
-    2nd sublicense agreement with a SUBLICENSEE: [***].
5.5.    In partial consideration for the license, LICENSEE shall grant to YALE rights to participate as an investor in LICENSEE, such that if LICENSEE proposes to sell any equity securities or securities that are convertible into equity securities of LICENSEE (collectively, "Equity Securities") in any preferred stock financing round, then YALE and/or its Assignee (as defined below) will have the right to invest up to the greater of either [***] or [***] on the same terms and conditions as are offered to other investors with respect to such Equity Securities sold in such financing.  The term "Assignee" means (a) any entity under the control (directly or indirectly) of [***], or (b) any entity that is controlled by YALE, provided such entity is an “accredited investor” within the meaning of Federal securities laws. 
5.6.    Coincident with CHANGE OF CONTROL, LICENSEE shall pay to YALE a non-refundable change of control fee (“CHANGE OF CONTROL FEE”) according to the following schedule: 
(a)    For a CHANGE OF CONTROL transaction that results in AGGREGATE NET PROCEEDS of [***], the CHANGE OF CONTROL milestone payment shall be [***].
(b)    For a CHANGE OF CONTROL transaction that results in Aggregate Net Proceeds of [***], the CHANGE OF CONTROL milestone payment shall be the greater of (i) [***] of the Aggregate Net Proceeds or (ii) [***];
(c)    For any CHANGE OF CONTROL, any cash received by YALE from any equity interest that YALE may have in LICENSEE or LICENSEE’s AFFILIATES at the time of such a CHANGE OF CONTROL will be credited against the CHANGE OF CONTROL FEE due to YALE.

									
	[***]
	 -11- 
	

Yale Confidential

5.7.    YALE shall be entitled to one seat on the Board of Directors of LICENSEE with equal voting rights to other board members. YALE agrees that, upon receiving a bona fide investment from a single investor or group of investors of [***], LICENSEE may convert the seat provided to YALE on the Board of Directors under this section 5.7 to an observer seat. If LICENSEE has obligations to provide YALE a seat on the Board of Directors of LICENSEE pursuant to another agreement other than this LICENSE, YALE agrees that it shall limit its representation on the Board of Directors to one designee.

6.    EARNED ROYALTIES
6.1.    During the TERM of this Agreement, as partial consideration for the LICENSE, LICENSEE shall pay to YALE an earned royalty of [***] on worldwide cumulative NET SALES of LICENSED PRODUCTS by LICENSEE or AFFILIATES except in the case of non-consumable electronic hardware, which will be subject to an earned royalty of [***] of NET SALES (“EARNED ROYALTY”).  In the event that NET SALES are made by a SUBLICENSEE, then the EARNED ROYALTY paid to YALE shall be reduced by [***].
Such EARNED ROYALTY shall be reduced by [***] if the LICENSED PRODUCT is not covered by a VALID CLAIM, but where the LICENSED PRODUCT has utilized, in part or in whole, any LICENSED INFORMATION for its discovery, development, manufacture, use, or sale. At the end of the TERM, on a country-by-country basis, no further royalties shall accrue and the LICENSE shall become non-exclusive, fully paid-up and royalty-free for such LICENSED PRODUCT in that country.
In the event that LICENSEE determines in good faith that rights to intellectual property owned or controlled by a third party are required to research, develop, make, import, use, sell, offer for sale, manufacture or fully commercialize the LICENSED PRODUCT (in addition to LICENSED PATENTS) , LICENSEE shall be entitled to offset [***] of any amounts paid to such third party against payments due to YALE; provided that in no event shall the amounts payable to YALE from LICENSEE on any LICENSED PRODUCT or LICENSED METHOD be reduced below by more than [***] of the amounts otherwise due to YALE in any calendar year, and provided further that any royalties due to any third party that are not offset in the applicable royalty period shall not be carried forward for offset in a subsequent period. 
6.2.    In the event that (i) LICENSEE or any of its AFFILIATES or SUBLICENSEES brings a PATENT CHALLENGE anywhere in the world, or (ii) LICENSEE or any of its AFFILIATES or SUBLICENSEES assists another party in bringing a PATENT CHALLENGE anywhere in the world (except as required under a court order or subpoena), and (iii) YALE does not choose to exercise its rights to terminate this Agreement pursuant to Article 13, then the following provisions shall apply.
									
	[***]
	 -12- 
	

Yale Confidential

(a)    All payments due to YALE under this Agreement other than patent costs shall be [***] during the pendency of the PATENT CHALLENGE and shall remain payable to YALE when due.
(b)    If the PATENT CHALLENGE is inconclusive or results in a determination that at least one challenged claim is both valid and infringed, 
(1) all payments due to YALE under this Agreement other than patent costs shall be [***] for the remainder of the TERM of the Agreement.
(2) LICENSEE shall promptly reimburse YALE for all legal fees and expenses incurred in YALE’s defense against the PATENT CHALLENGE. 
(c)    In the event that such a PATENT CHALLENGE is successful, LICENSEE will have no right to recoup any payments made prior to the final, non-appealable determination of a court of competent jurisdiction.
6.3.    Neither LICENSEE nor any of its AFFILIATES or SUBLICENSEES shall bring a PATENT CHALLENGE without first providing YALE [***] written notice setting forth (a) precisely which claims and patents are being challenged or claimed not to be infringed, (b) a clear statement of the factual and legal basis for the challenge, and (c) an identification of all prior art and other matter believed to invalidate any claim of the LICENSED PATENT or which supports the claim that the LICENSED PATENT is not infringed.
6.4.    LICENSEE shall pay all EARNED ROYALTIES accruing to YALE within [***] days from the end of each calendar quarter (March 31, June 30, September 30 and December 31), beginning in the first calendar quarter in which NET SALES occur.  Unless YALE requests otherwise, LICENSEE shall report all EARNED ROYALTIES and other payments accruing to YALE on a quarterly basis, but shall defer payments accruing to YALE that do not, in total, exceed [***] in any given quarter until the earlier of (1) the end of the calendar year, or (2) the quarter upon which the cumulative accrued royalties and other payments exceed [***]. 
6.5    All EARNED ROYALTIES and other payments due under this Agreement shall be paid to YALE in United States Dollars.  In the event that conversion from foreign currency is required in calculating a payment under this Agreement, the exchange rate used shall be the Interbank rate quoted by Citibank at the end of the last business day of the quarter in which the royalty was earned. If overdue, the royalties and any other payments due under this Agreement shall bear interest until payment at a per annum rate [***] above the prime rate in effect at Citibank on the due date and YALE shall be entitled to recover reasonable attorneys’ fees and costs related to the administration or enforcement of this Agreement, including collection of royalties or other payments, following such failure to pay.  The payment of such interest shall not foreclose YALE from exercising any other right it may have as a consequence of the failure of LICENSEE to make any payment when due.

									
	[***]
	 -13- 
	

Yale Confidential

7.    SUBLICENSES
7.1.    LICENSEE shall have the right to sublicense to SUBLICENSEES any of the rights granted in section 3.1 above, subject to the provisions of Articles 7.2, 7.3 and 7.4.
7.2.    Any sublicense granted by LICENSEE shall include substantially the same definitions and provisions, and such other provisions as are needed to enable LICENSEE to provide Yale the protections and benefits contemplated herein. LICENSEE will provide YALE with a copy of each sublicense agreement (and all amendments thereof) promptly after execution. LICENSEE shall also include provisions in all sublicenses to provide that in the event that SUBLICENSEE brings a PATENT CHALLENGE anywhere in the world or assists another party in bringing a PATENT CHALLENGE anywhere in the world (except as required under a court order or subpoena) then LICENSEE shall immediately terminate the sublicense. LICENSEE shall remain responsible for the performance of all SUBLICENSEES under any such sublicense as if such performance were carried out by LICENSEE itself. A breach of this provision shall constitute a material breach that is subject to Article 13.1(b).
7.3.    LICENSEE shall pay to YALE [***], as adjusted from time to time as provided below, of any SUBLICENSE INCOME.
7.4.    LICENSEE agrees that it has sole responsibility to promptly: 
(a)    provide YALE with a copy of any amendments to sublicenses granted by LICENSEE under this Agreement and to notify YALE of termination of any sublicense; and
(b)    summarize and deliver copies of all reports provided to LICENSEE by SUBLICENSEES.
8.    CONFIDENTIALITY AND PUBLICITY
8.1.    Subject to the parties’ rights and obligations pursuant to this Agreement, YALE and LICENSEE agree that during the term of this Agreement and for [***] years thereafter, each of them:
(a)    will keep confidential and will cause their AFFILIATES and, in the case of LICENSEE, its SUBLICENSEES, to keep confidential, CONFIDENTIAL INFORMATION disclosed to it by the other party, by taking whatever action the party receiving the CONFIDENTIAL INFORMATION would take to preserve the confidentiality of its own CONFIDENTIAL INFORMATION, which in no event shall be less than reasonable care; and
(b)    will only disclose that part of the other’s CONFIDENTIAL INFORMATION to its officers, employees or agents, under requirements of confidentiality, for purposes of carrying out its rights and responsibilities under this Agreement; and
(c)    will not use the other party’s CONFIDENTIAL INFORMATION other than as expressly permitted by this Agreement or disclose the other’s 
									
	[***]
	 -14- 
	

Yale Confidential

CONFIDENTIAL INFORMATION to any third parties (other than to agents under requirements of confidentiality) under any circumstance without advance written permission from the other party; and
(d)    will, within [***] days of termination of this Agreement, return all the CONFIDENTIAL INFORMATION disclosed to it by the other party pursuant to this Agreement except for one copy which may be retained by the recipient for monitoring compliance with this Article 8 and any surviving clauses.
8.2.    The obligations of confidentiality described above shall not pertain to that part of the CONFIDENTIAL INFORMATION that:
(a)    is shown to have been known to or developed by the recipient prior to the disclosure by the disclosing party; or
(b)    is at the time of disclosure or has become thereafter publicly known through no fault or omission attributable to the recipient; or 
(c)    is rightfully given to the recipient from sources independent of the disclosing party; or
(d)    is independently developed by the receiving party without use of or reference to the CONFIDENTIAL INFORMATION of the other party; or
(e)    is required to be disclosed by law in the opinion of recipient’s attorney, but only after the disclosing party is given prompt written notice and an opportunity to seek a protective order.  
8.3.    The financial terms of this Agreement constitute CONFIDENTIAL INFORMATION of each party, provided, however, YALE hereby grants its advance written permission to the LICENSEE to share the financial terms of this Agreement with those potential investors that are bound under substantially similar confidentiality terms to this Section 8 with the LICENSEE.
9.    REPORTS, RECORDS AND INSPECTIONS
9.1.    LICENSEE shall, within [***] days after the calendar year in which NET SALES first occur, and within [***] days after each calendar quarter (March 31, June 30, September 30 and December 31) thereafter, provide YALE with a written report detailing the NET SALES and uses, if any, made by LICENSEE, its SUBLICENSEES and AFFILIATES of LICENSED PRODUCTS during the preceding calendar quarter and calculating the payments due pursuant to Article 6.  NET SALES of LICENSED PRODUCTS shall be deemed to have occurred on the date of invoice for such LICENSED PRODUCTS.  Each such report shall be signed by an officer of LICENSEE (or the officer's designee), and must include:
(a)    the number or amount, as appropriate, of LICENSED PRODUCTS manufactured, sold, practiced, leased or otherwise transferred or disposed of by LICENSEE, SUBLICENSEES and AFFILIATES;
(b)    a calculation of NET SALES for the applicable reporting period in each country, including the gross invoice prices charged for the LICENSED PRODUCTS and any permitted deductions made pursuant to Article 2.19;
									
	[***]
	 -15- 
	

Yale Confidential

(c)    a calculation of total royalties or other payment due, including any exchange rates used for conversion; and 
(d)    names and addresses of all SUBLICENSEES and the type and amount of any SUBLICENSE INCOME received from each SUBLICENSEE; and
(e)    identification of any INVENTOR AGREEMENT(S) in effect during the previous calendar quarter.
9.2.    LICENSEE, AFFILIATES and its SUBLICENSEES shall keep and maintain complete and accurate records and books containing an accurate accounting of all data in sufficient detail to enable verification of EARNED ROYALTIES and other payments under this Agreement.  LICENSEE shall preserve such books and records for [***] years after the calendar year to which they pertain.  Such books and records shall be open to inspection by YALE or an independent certified public accountant selected by YALE, at YALE’s expense, during normal business hours upon [***] days' prior written notice, for the purpose of verifying the accuracy of the reports and computations rendered by LICENSEE.  In the event LICENSEE underpaid the amounts due to YALE with respect to the audited period by more than [***], LICENSEE shall pay the reasonable cost of such examination, together with the deficiency not previously paid and interest from the due date of such payment, calculated at the rate set forth in Article 6.5, within [***] days of receiving notice thereof from YALE. 
9.3.    On or before the [***] day following the close of LICENSEE’s fiscal year, LICENSEE shall provide YALE with LICENSEE’s certified financial statements for the preceding fiscal year including, at a minimum, a balance sheet and an income statement.
10.    PATENT PROTECTION
10.1.    LICENSEE shall be responsible for all past, present and future costs of filing, prosecution and maintenance of all United States patent applications contained in the LICENSED PATENTS.  Any and all such United States patent applications, and resulting issued patents, shall remain the property of YALE. 
10.2.    LICENSEE shall be responsible for all past, present and future costs of filing, prosecution and maintenance of all foreign patent applications, and patents contained in the LICENSED PATENTS in the countries outside the United States in the LICENSED TERRITORY selected by YALE and agreed to by LICENSEE.  All such applications or patents shall remain the property of YALE.  LICENSEE acknowledges that YALE shall not be required to file any such applications in low or lower-middle income countries, as designated by the World Bank (www.worldbank.org).  Furthermore, LICENSEE agrees not to file any patent rights that are owned by LICENSEE and that claim LICENSED PRODUCTS in any such low-income or lower-middle income countries.  
10.3.    Prior to SUCCESSFUL FINANCING, and for as long as there is an outstanding balance of unreimbursed patent expenses, LICENSEE shall pay to YALE [***] due monthly, beginning on the EFFECTIVE DATE. Upon SUCCESSFUL FINANCING, all patent expenses, including all outstanding balances of unreimbursed patent expenses, will be paid [***] days of invoice from YALE.
									
	[***]
	 -16- 
	

Yale Confidential

10.4.    If, upon the request of YALE, LICENSEE does not agree in writing to pay the expenses of filing, prosecuting or maintaining a patent application or patent in any country outside the United States, or fails to pay the expenses of filing, prosecuting or maintaining a patent application or patent in the United States, then LICENSEE's rights under this Agreement shall terminate automatically with respect to that country.
10.5.    The costs mentioned in Articles 10.2, 10.3 and 10.4 shall include, but are not limited to, any past, present and future taxes, annuities, working fees, maintenance fees, renewal and extension charges. Payment of such costs shall be made, at YALE's option, either directly to patent counsel or by reimbursement to YALE.  In either case, LICENSEE shall make payment directly to the appropriate party within [***] days of receiving its invoice.  If LICENSEE fails to make payment to YALE or patent counsel, as appropriate, within the [***] day period, LICENSEE shall be charged a [***] surcharge on the invoiced amount plus interest at the rate of [***] per month or fraction thereof or such higher amount as may be charged by patent counsel.  Failure of LICENSEE to pay the costs shall be grounds for termination by YALE under Article 13.1(b).
10.6.    All patent applications under the LICENSED PATENTS shall be prepared, prosecuted, filed and maintained by independent patent counsel chosen by YALE and reasonably acceptable to LICENSEE.  Said independent patent counsel shall be ultimately responsible to YALE. YALE shall instruct patent counsel to keep both YALE and LICENSEE fully informed of the progress of all patent applications and patents, and to give both YALE and LICENSEE reasonable opportunity to comment on the type and scope of useful claims and the nature of supporting disclosures. YALE will not finally abandon any patent application for which LICENSEE is bearing expenses without LICENSEE's consent.  YALE shall have no liability to LICENSEE for damages, whether direct, indirect or incidental, consequential or otherwise, allegedly arising from its good faith decisions, actions and omissions in connection with such prosecution.
10.7.    LICENSEE shall mark, and shall require AFFILIATES and SUBLICENSEES to mark, all LICENSED PRODUCTS, that are tangible products, with the numbers of all patents included in LICENSED PATENTS that cover the LICENSED PRODUCTS.  Without limiting the foregoing, all LICENSED PRODUCTS shall be marked in such a manner as to conform with the patent marking notices required by the law of any country where such LICENSED PRODUCTS are made, sold, used or shipped, including, but not limited to, the applicable patent laws of that country.
11.    INFRINGEMENT AND LITIGATION
11.1.    Each party shall promptly notify the other in writing in the event that it obtains knowledge of infringing activity by third parties, or is sued or threatened with an infringement suit, in any country in the LICENSED TERRITORY as a result of activities that concern the LICENSED PATENTS, and shall supply the other party with documentation of the infringing activities that it possesses.
11.2.    During the TERM of this Agreement:
(a)    LICENSEE shall have the first right and obligation to defend the LICENSED PATENTS against infringement or interference in the FIELD and in the LICENSED TERRITORY by third parties.  This right and 
									
	[***]
	 -17- 
	

Yale Confidential

obligation includes bringing any legal action for infringement and defending any counter claim of invalidity or action of a third party for declaratory judgment for non-infringement or non-interference.  If, in the reasonable opinion of both LICENSEE’s and YALE’s respective counsel, YALE is required to be a named party to any such suit for standing purposes, LICENSEE may join YALE as a party; provided, however, that (i) YALE shall not be the first named party in any such action, (ii) the pleadings and any public statements about the action shall state that the action is being pursued by LICENSEE and that LICENSEE has joined YALE as a party; and (iii) LICENSEE shall keep YALE reasonably apprised of all developments in any such action.  LICENSEE may settle such suits solely in its own name and solely at its own expense and through counsel of its own selection; provided, however, that no settlement shall be entered without YALE’s prior written consent, such consent not to be unreasonably withheld.  Without limiting the foregoing, YALE may withhold its consent to any settlement that would in any manner constitute or incorporate an admission by YALE or require YALE to take or refrain from taking any action.  LICENSEE shall bear the expense of such legal actions.  Except for providing reasonable assistance, at the request and expense of LICENSEE, YALE shall have no obligation regarding the legal actions described in Article 11.2 unless required to participate by law.  However, YALE shall have the right to participate in any such action through its own counsel and at its own expense.  Any recovery shall first be applied to LICENSEE’s out of pocket expenses and second shall be applied to YALE's out of pocket expenses, including legal fees.  YALE shall recover [***] of any excess recovery over those expenses.  
(b)    In the event LICENSEE fails to initiate and pursue or participate in the actions described in Article (a) within [***] days of (a) notification of infringement from YALE or (b) the date LICENSEE otherwise first becomes aware of an infringement, whichever is earlier, YALE may, in its sole discretion, convert the LICENSE granted in Article 3 to a nonexclusive license, and issue licenses to third parties under the LICENSED PATENTS to make, have made, use, sell, have sold, import, export, or practice LICENSED PRODUCTS within the FIELD in the LICENSED TERRITORY. Additionally, YALE shall have the right to initiate legal action such as that described in Article 11.2(a) at its own expense and YALE may use the name of LICENSEE as party plaintiff to uphold the LICENSED PATENTS.  In such case, LICENSEE shall provide reasonable assistance to YALE if requested to do so.  YALE may settle such actions solely through its own counsel.  Any recovery shall be retained by YALE. YALE may terminate the LICENSE in the country where such legal action is taken. 
(c)    In the event LICENSEE is permanently enjoined from exercising its LICENSE under this Agreement pursuant to an infringement action brought by a third party, or if both LICENSEE and YALE elect not to undertake the defense or settlement of a suit alleging infringement for a period of [***] months from notice of such suit, then either party shall have the right to terminate this Agreement in the country where the suit was filed with respect to the licensed patent following [***] days’ written notice to the other party in accordance with the terms of Article 15.
									
	[***]
	 -18- 
	

Yale Confidential

(d)    Notwithstanding the foregoing, neither LICENSEE nor YALE shall take any action to enforce the LICENSED PATENTS, or patent rights owned by LICENSEE and which claim the LICENSED PRODUCTS, in low or lower-middle income countries, where such action is intended to prevent the sale of LICENSED PRODUCTS in any such countries.  However, LICENSEE and/or YALE may take such action in any such country, provided that such action is intended to prevent the manufacturing of LICENSED PRODUCTS for export to countries that are not low-income or lower-middle countries.  
12.    USE OF YALE’S NAME
12.1.    LICENSEE shall not use the name “Yale” or “Yale University,” nor any variation or adaptation thereof, nor any trademark, tradename or other designation owned by YALE, nor the names of any of its trustees, officers, faculty, students, employees or agents, for any purpose without the prior written consent of YALE in each instance, such consent to be granted or withheld by YALE in its sole discretion, except that LICENSEE may state that it has licensed from YALE one or more of the patents and/or applications comprising the LICENSED PATENTS and LICENSEE may state the relationship of the INVENTORS to YALE and how the INVENTOR’s research at YALE relates to such patents and/or inventions. 
13.    TERMINATION
13.1.    YALE shall have the right to terminate this Agreement upon written notice to LICENSEE in the event LICENSEE:
(a)    fails to make any payment whatsoever due and payable pursuant to this Agreement unless LICENSEE shall make all such payments (and all interest due on such payments under Article 6.4) within the [***] day period after receipt of written notice from YALE; or
(b)    commits a material breach of any other provision of this Agreement which is not cured (if capable of being cured) within the [***] day period after receipt of written notice thereof from YALE, or upon receipt of such notice if such breach is not capable of being cured; or
(c)    fails to obtain or maintain adequate insurance as described in Article 14.2, whereupon YALE may terminate this Agreement immediately upon written notice to LICENSEE. 
(d)    If LICENSEE or any of its AFFILATES brings a PATENT CHALLENGE against YALE, or assists others in bringing a PATENT CHALLENGE against YALE (except as required under a court order or subpoena), whereupon YALE may terminate this Agreement immediately.  
(e)    If a SUBLICENSEE brings a PATENT CHALLENGE or assists another party in bringing a PATENT CHALLENGE (except as required under a court order or subpoena), then YALE may send a written demand to LICENSEE to terminate such sublicense.  If LICENSEE fails to so terminate such sublicense within [***] days after YALE’s demand, YALE may immediately terminate this Agreement. 
									
	[***]
	 -19- 
	

Yale Confidential

13.2.    This Agreement shall terminate automatically without any notice to LICENSEE in the event LICENSEE shall cease to carry on its business for a continuous period of [***] days or becomes INSOLVENT, or a petition in bankruptcy is filed against LICENSEE and is consented to, acquiesced in or remains undismissed for [***] days, or LICENSEE makes a general assignment for the benefit of creditors, or a receiver is appointed for LICENSEE.
13.3.    LICENSEE shall have the right to terminate this Agreement upon written notice to YALE:
(a)    at any time on [***] months’ notice to YALE, provided LICENSEE is not in breach and upon payment of all amounts due YALE throughout the effective date of termination; or
(b)    in the event YALE commits a material breach of any of the provisions of this Agreement and such breach is not cured (if capable of being cured) within the [***] day period after receipt of written notice thereof from LICENSEE, or upon receipt of such notice if such breach is not capable of being cured. 
13.4.    Upon termination of this Agreement pursuant to Sections 13.1 through 13.3 but not natural expiration pursuant to Section 3.4), all rights and licenses granted to LICENSEE under the terms of this Agreement are terminated and YALE has the option, in its discretion, to terminate any sublicense granted by LICENSEE.  Upon such termination, LICENSEE shall cease to make, have made, use, sell, have sold, distribute, practice, import or export LICENSED PRODUCTS.  Within [***] days of the effective date of termination LICENSEE shall return to YALE:
(a)    All CONFIDENTIAL INFORMATION disclosed by YALE;
(b)    the last report required under Article 4 or Article 9; and 
(c)    all payments incurred up to the effective date of termination.
13.5.    Termination of this Agreement shall not affect any rights or obligations accrued prior to the effective date of such termination and specifically LICENSEE’s obligation to pay all royalties and other payments specified by Article 4 and Article 6.  In particular, but without limitation, the following provisions shall survive any termination:  Articles 2 and 8, the preservation and inspection obligations of Article 9, Article 12, this Article 13.5, Article 13.6, Article 13.8, Article 14, Article 15, Article 17.1, and Article 18.  The parties agree that claims giving rise to indemnification may arise after the TERM or termination of the LICENSE granted herein.
13.6.    The rights provided in this Article 13 shall be in addition and without prejudice to any other rights, whether at law or in equity, which the parties may have with respect to any default or breach of the provisions of this Agreement.
13.7.    Waiver by either party of one or more defaults or breaches shall not deprive such party of the right to terminate because of any subsequent default or breach.
13.8.    Upon termination of this Agreement for any reason other than breach by YALE or expiration pursuant to Section 3.4, and subject to all third party rights, LICENSEE 
									
	[***]
	 -20- 
	

Yale Confidential

shall permit YALE and its future licensees to utilize, reference and otherwise have the benefit of all regulatory approvals of, or clinical trials or other studies conducted on, and all filings made with regulatory agencies with respect to, the LICENSED PRODUCTS.  In addition, at YALE's request, LICENSEE shall deliver to YALE within [***] months of such request all records required by regulatory authorities to be maintained with respect to the sale, storage, handling, shipping and use of the LICENSED PRODUCTS, all reimbursement approval files, all documents, data and information related to clinical trials and other studies of LICENSED PRODUCTS, any other data, techniques, know-how and other information developed or generated that relate to the LICENSED PATENTS or LICENSED PRODUCTS, and all copies and facsimiles of such materials, documents, information and files.  YALE agrees that, subject to the provisions of Article 8, LICENSEE may retain one copy thereof to the extent LICENSEE is required by law to maintain such copy.  In the event that YALE executes a license agreement with a future licensee for the information granted to YALE pursuant to this Article 13.8, YALE shall pay to LICENSEE, up to an amount equal to [***] of LICENSEE’s documented development costs incurred under this Agreement, a revenue share of [***] on all consideration received from such licensee allocable to LICENSED PRODUCTS or sales thereof, including (a) all upfront and other payments payable to YALE upon execution of such license agreement with such licensee; (b) any development, regulatory or commercialization milestone payments for milestones occurring under any such license agreement; (c) license maintenance fees under any such license agreement; (d) any payments to YALE for the supply of LICENSED PRODUCTS; (e) royalties, profit share payments and other payments based on the sales of LICENSED PRODUCTS; and (f) the fair market value of any other form of consideration paid to YALE by such licensee for a license under any intellectual property or other rights granted to YALE by such licensee pursuant to this Article 13.8, but excluding YALE’s cost of goods to procure or manufacture LICENSED PRODUCTS for which payments under clause (d) above are made to YALE.   
14.    INDEMNIFICATION; INSURANCE; NO WARRANTIES
14.1.    LICENSEE shall indemnify, defend by counsel acceptable to YALE, and hold harmless YALE and its trustees, officers, employees, and agents (collectively, “YALE Indemnitees”), from and against any claim, liability, cost, expense, damage, deficiency, loss, or obligation, of any kind or nature (including, without limitation, reasonable attorneys’ fees and other costs and expenses of defense) (collectively, “CLAIMS”), based upon, arising out of or otherwise relating to this LICENSE, including without limitation any cause of action relating to product liability, or any theory of liability (including without limitation tort, warranty, or strict liability) or the death, personal injury, or illness of any person or out of damage to any property related in any way to the rights granted under this Agreement; or resulting from the production, manufacture, sale, use, lease, or other disposition or consumption or advertisement of the LICENSED PRODUCTS by LICENSEE, its AFFILIATES, SUBLICENSEES or any other transferees; or in connection with any statement, representation or warranty of LICENSEE, its AFFILIATES, SUBLICENSEES or any other transferees with respect to the LICENSED PRODUCTS. LICENSEE shall not settle or compromise the CLAIM without the prior written consent of YALE, such consent not to be unreasonably withheld.  Without limiting the foregoing, YALE may withhold its consent to any settlement or compromise that would in any manner constitute or incorporate an admission by YALE or require YALE to take or refrain from taking any action.
									
	[***]
	 -21- 
	

Yale Confidential

14.2.    LICENSEE shall purchase and maintain in effect and shall require its SUBLICENSEES to purchase and maintain in effect a policy of commercial, general liability insurance to protect YALE with respect to events described in Article 14.1.  Such insurance shall:
(a)    list “YALE, its trustees, directors, officers, employees and agents” as additional insureds under the policy;
(b)    provide that such policy is primary and not excess or contributory with regard to other insurance YALE may have;
(c)    be endorsed to include product liability coverage in amounts no less than [***] Dollars per incident and [***] Dollars annual aggregate; and
(d)    be endorsed to include contractual liability coverage for LICENSEE’s indemnification under Article 14.1; and
(e)    by virtue of the minimum amount of insurance coverage required under Article 14.2(c), not be construed to create a limit of LICENSEE’s liability with respect to its indemnification under Article 14.1.
14.3.    By signing this Agreement, LICENSEE certifies that the requirements of Article 14.2 will be met on or before the earlier of (a) the date of FIRST SALE of any LICENSED PRODUCT or (b) the date any LICENSED PRODUCT is tested or used on humans, and will continue to be met thereafter, and, before the earlier of either (a) or (b), LICENSEE shall furnish a Certificate of Insurance and a copy of the current insurance policy to YALE.  LICENSEE shall secure agreement from its insurer to give [***] days’ written notice to YALE prior to any cancellation of or material change to the policy.
(a)    YALE MAKES NO, AND EXPRESSLY DISCLAIMS ALL, REPRESENTATIONS OR WARRANTIES THAT ANY CLAIMS OF THE LICENSED PATENTS, ISSUED OR PENDING, ARE VALID, OR THAT THE MANUFACTURE, USE, PRACTICE, SALE OR OTHER DISPOSAL OF THE LICENSED PRODUCTS DOES NOT OR WILL NOT INFRINGE UPON ANY PATENT OR OTHER RIGHTS NOT VESTED IN YALE.
(b)    YALE MAKES NO, AND EXPRESSLY DISCLAIMS ALL, REPRESENTATIONS AND WARRANTIES WHATSOEVER WITH RESPECT TO THE LICENSED PATENTS AND LICENSED PRODUCTS, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.  
(c)    LICENSEE SHALL MAKE NO STATEMENTS, REPRESENTATION OR WARRANTIES WHATSOEVER TO ANY THIRD PARTIES THAT ARE INCONSISTENT WITH THE DISCLAIMERS BY YALE IN ARTICLE 14.3(a) AND (b).  
(d)    IN NO EVENT SHALL YALE, OR ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES BE LIABLE FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL OR INDIRECT DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGE OR INJURY TO PROPERTY 
									
	[***]
	 -22- 
	

Yale Confidential

AND LOST PROFITS, REGARDLESS OF WHETHER YALE SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING.  
(e)    IN NO EVENT SHALL YALE, OR ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES, BE LIABLE FOR DAMAGES IN EXCESS OF AMOUNTS YALE HAS RECEIVED FROM LICENSEE UNDER THIS LICENSE.
15.    NOTICES
15.1.    Any monetary payment, notice or other communication required by this Agreement (a) shall be in writing, (b) may be delivered personally or sent by reputable overnight courier with written verification of receipt or by registered or certified first class United States Mail, postage prepaid, return receipt requested, (c) shall be sent to the following addresses or to such other address as such party shall designate by written notice to the other party, and (d) shall be effective upon receipt:
						
	FOR YALE:	FOR LICENSEE: 
	Managing Director
YALE UNIVERSITY
Office of Cooperative Research
433 Temple Street
New Haven, CT 06511	Chief Executive Officer
IsoPlexis Corporation
51 Cottage, Unit 3
New Haven, CT 06511

16.    INVENTOR AGREEMENTS
16.1    If LICENSEE and INVENTOR enter into an INVENTOR AGREEMENT, LICENSEE shall so notify YALE in writing within [***] days.  The LICENSEE acknowledges that: (i) the INVENTOR is a faculty member, other employee, or student of YALE; (ii) the INVENTOR is subject to certain policies of YALE, as such policies may be revised from time to time, including policies concerning consulting, conflicts of interest, and intellectual property (“YALE POLICIES”); (iii) to the extent any provision of the INVENTOR AGREEMENT conflicts with YALE POLICIES, or imposes obligations or responsibilities compliance with which would require the INVENTOR to act in violation of YALE POLICIES, such provision shall be void.  INVENTOR is a third party beneficiary of this paragraph.  

17.    LAWS, FORUM AND REGULATIONS
17.1.    Any matter arising out of or related to this Agreement shall be governed by and in accordance with the substantive laws of the State of Connecticut, without regard to its conflicts of law principles, except where the federal laws of the United States are applicable and have precedence.  Any dispute arising out of or related to this Agreement shall be brought exclusively in a court of competent jurisdiction in the State of Connecticut, and the parties hereby irrevocably submit to the jurisdiction of such courts.  
17.2.    LICENSEE shall comply, and shall cause its AFFILIATES and SUBLICENSEES to comply, with all foreign and United States federal, state, and local laws, regulations, rules and orders applicable to the testing, production, transportation, 
									
	[***]
	 -23- 
	

Yale Confidential

packaging, labeling, export, practice, sale and use of the LICENSED PRODUCTS.  In particular, LICENSEE shall be responsible for assuring compliance with all United States export laws and regulations applicable to this LICENSE and LICENSEE’s activities under this Agreement.
18.    MISCELLANEOUS
18.1.    This Agreement shall be binding upon and inure to the benefit of the parties and their respective legal representatives, successors and permitted assigns.
18.2.    This Agreement constitutes the entire agreement of the parties relating to the LICENSED PATENTS and LICENSED PRODUCTS, and all prior representations, agreements and understandings, written or oral, including the Original Agreement, as amended and restated on July 15, 2014, are merged into it and are superseded by this Agreement.
18.3.    The provisions of this Agreement shall be deemed separable.  If any part of this Agreement is rendered void, invalid, or unenforceable, such determination shall not affect the validity or enforceability of the remainder of this Agreement unless the part or parts which are void, invalid or unenforceable shall substantially impair the value of the entire Agreement as to either party.
18.4.    Paragraph headings are inserted for convenience of reference only and do not form a part of this Agreement.
18.5.    No person not a party to this Agreement, including any employee of any party to this Agreement, shall have or acquire any rights by reason of this Agreement.  Nothing contained in this Agreement shall be deemed to constitute the parties partners or joint venturers with each other or any third party, and neither party shall be deemed the agent of the other.
18.6.    This Agreement may not be amended or modified except by written agreement executed by each of the parties.  This Agreement is personal to LICENSEE and shall not be assigned by LICENSEE without the prior written consent of YALE, not to be unreasonably withheld. .  Any attempted assignment in contravention of this Article 18.6 shall be null and void and shall constitute a material breach of this Agreement.  
18.7.    LICENSEE, or any SUBLICENSEE or assignee, will not create, assume or permit to exist any lien, pledge, security interest or other encumbrance on this Agreement or any sublicense.
18.8.    The failure of any party hereto to enforce at any time, or for any period of time, any provision of this Agreement shall not be construed as a waiver of either such provision or of the right of such party thereafter to enforce each and every provision of this Agreement.
18.9.    This Agreement may be executed in any number of counterparts and any party may execute any such counterpart, each of which when executed and delivered shall be deemed to be an original and all of which counterparts taken together shall constitute but one and the same instrument.
Signature Page Follows
									
	[***]
	 -24- 
	

Yale Confidential

IN WITNESS to their Agreement, the parties have caused this Agreement to be executed in duplicate originals by their duly authorized representatives.
															
	YALE UNIVERSITY		ISOPLEXIS CORPORATION
					
	By:	/s/ Jonathan Soderstrom		By:	/s/ Sean Mackay
					
	E. Jonathan Soderstrom, Ph.D.
		Sean Mackay

					
	Managing Director
			
					
	Office of Cooperative Research
		Chief Executive Officer

					
	Date:	24 November 2015		Date:	28 November 2015

									
	[***]
	 -25- 
	

Yale Confidential

Appendix A
LICENSED PATENTS1
[***]

1 As of the RESTATEMENT DATE.
									
	[***]
	 -26- 
	

Yale Confidential

Appendix B
LICENSED INFORMATION
[***]
									
	[***]
	 -27- 
	

Yale Confidential

Appendix C
PLAN
[***]
									
	[***]
	 -28-Document

Exhibit 10.4

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is the type that the registrant customarily and actually treats as private and confidential.
AMENDMENT TO THE LICENSE AGREEMENT [***]
Between IsoPlexis Corporation (“ISOPLEXIS”) and Yale University (“YALE”)
PREAMBLE
1)    The Parties entered into a license agreement effective April 25, 2014, which was amended and restated July 15, 2014, which was then amended and restated November 28, 2015 (together, the “Agreement”).
2)    The parties are willing to amend the Agreement in accordance with this Amendment (the “Amendment”).
3)    All other terms of the Agreement shall remain unchanged.
NOW THEREFORE IT IS AGREED AS FOLLOWS:
1.    AMENDMENTS TO THE AGREEMENT
i)    Appendix A of the Agreement shall be modified to include the following as Licensed Patents, in addition to the previously listed Licensed Patents:
[***]
ii)    As partial consideration for the inclusion of the above patent applications in this Amendment, ISOPLEXIS shall pay to YALE [***], which is intended to reflect unreimbursed patent expenses incurred prior to the date of execution of this Amendment.
2.    CONTINUATION OF THE AGREEMENT:
The Agreement remains in full force as supplemented and amended by this Amendment.  Except as expressly specified in this Amendment, the Agreement is not amended and the terms and conditions contained therein remain unchanged.

This Amendment enters into force upon its execution by the Parties.
																		
	YALE UNIVERSITY		ISOPLEXIS	
						
	By:	/s/ Jonathan Soderstrom		By:	/s/ Sean Mackay	
				
	E. Jonathan Soderstrom, Ph.D.		Name:  Sean MacKay	
	Managing Director 				
	Office of Cooperative Research		Title:    Chief Executive Officer	
						
	Date:	19 Dec 2016		Date:	12/16/16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]